BRAIN Biotech (BNN) Stock Overview
Provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BNN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.28 |
| 52 Week High | €4.40 |
| 52 Week Low | €1.42 |
| Beta | 0.76 |
| 1 Month Change | 3.64% |
| 3 Month Change | 8.57% |
| 1 Year Change | 31.79% |
| 3 Year Change | -65.45% |
| 5 Year Change | -71.57% |
| Change since IPO | -74.94% |
Recent News & Updates
Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Aug 26
A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb
Jul 23Recent updates
Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Aug 26A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb
Jul 23Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce
Nov 12Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce
Sep 24BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch
Aug 06Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Jun 29BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate
Apr 19BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable
Mar 28Is BRAIN Biotech (ETR:BNN) A Risky Investment?
Feb 16Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt
Sep 13Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like
Mar 21Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?
Feb 14When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?
Jan 18How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 31
Shareholder Returns
| BNN | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 12.3% | -2.8% | 1.1% |
| 1Y | 31.8% | -5.5% | 17.4% |
Return vs Industry: BNN exceeded the German Chemicals industry which returned -5.5% over the past year.
Return vs Market: BNN exceeded the German Market which returned 17.4% over the past year.
Price Volatility
| BNN volatility | |
|---|---|
| BNN Average Weekly Movement | 11.3% |
| Chemicals Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BNN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BNN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 285 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates through three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production.
BRAIN Biotech AG Fundamentals Summary
| BNN fundamental statistics | |
|---|---|
| Market cap | €48.06m |
| Earnings (TTM) | -€13.66m |
| Revenue (TTM) | €53.52m |
Is BNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNN income statement (TTM) | |
|---|---|
| Revenue | €53.52m |
| Cost of Revenue | €24.39m |
| Gross Profit | €29.12m |
| Other Expenses | €42.78m |
| Earnings | -€13.66m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jan 14, 2026
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 54.42% |
| Net Profit Margin | -25.52% |
| Debt/Equity Ratio | 63.8% |
How did BNN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 17:37 |
| End of Day Share Price | 2025/08/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BRAIN Biotech AG is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Schwarz | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |